We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CRC Gut Microbial Signatures Lead to Diagnostic Tests

By LabMedica International staff writers
Posted on 18 Apr 2019
Print article
Image: A gram-negative stained culture of Fusobacterium nucleatum (Photo courtesy of J. Michael Miller, Ph.D., (D)ABMM).
Image: A gram-negative stained culture of Fusobacterium nucleatum (Photo courtesy of J. Michael Miller, Ph.D., (D)ABMM).
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that have the ability to invade or spread to other parts of the body.

Meta-analyses of metagenomic data are spelling out some of the roles that gut microbes play in CRC) and are suggesting new biomarkers for diagnostic and prognostic tests. Association studies have linked microbiome alterations with many human diseases. However, they have not always reported consistent results, thereby necessitating cross-study comparisons.

A team of international scientists collaborating with the University of Trento (Trento, Italy) elsewhere combined metagenomic data for 624 fecal samples from CRC patients and controls that were sequenced for five past studies and data from 140 newly-sequenced samples from two new cohorts. In the CRC samples, their analysis revealed gut microbial community enrichment and an increase in species typically linked to the oral microbiome, results they verified using data for two more cohorts comprised of 100 CRC cases and 105 controls.

The team focused on the specific microbial pathways that were over- or underrepresented in the CRC cases, and they observed an apparent rise in choline metabolism and enhanced activity by gluconeogenesis, putrefaction, and fermentation pathways. Compared to unaffected control individuals, the cases also appeared to have gut microbial communities with less active starch degradation and stachyose pathways. They also used the data to come up with a microbiome-based signature for distinguishing between individuals with or without CRC, including microbes such as Fusobacterium nucleatum, which has been implicated in CRC in the past. Pooled analysis of raw metagenomes showed that the choline trimethylamine-lyase gene was overabundant in CRC, identifying a relationship between microbiome choline metabolism and CRC.

The authors concluded that the combined analysis of heterogeneous CRC cohorts thus identified reproducible microbiome biomarkers and accurate disease-predictive models that can form the basis for clinical prognostic tests and hypothesis-driven mechanistic studies. Nicola Segata, PhD, an assistant professor and co-senior author of the study, said, “We not only established a panel of gut microbes associated with colorectal cancer across populations, but also found signatures in microbial metabolism that have similar predictive power. These will enable new studies aiming at understanding how gut microbes may contribute causally to cancer development. The study was published on April 1, 2019, in the journal Nature Medicine.

Related Links:
University of Trento

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more